首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1370889

全球地中海貧血治療市場-產業規模、佔有率、趨勢、機會和預測，2018-2028F 按類型（輸血、鐵螯合療法、血液和骨髓移植等）、地區和競爭細分

Global Thalassemia Treatment Market- Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, and Others), By Region and Competition

出版日期: 2023年10月03日 | 出版商:

TechSci Research | 英文 189 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

全球地中海貧血治療市場在2024-2028年預測期內將出現令人印象深刻的成長。這可以歸因於地中海貧血及其治療方案的日益普及。地中海貧血是許多發展中國家，特別是地中海地區的一個主要公共衛生問題。疾病的沉重負擔對有效的地中海貧血疫苗產生了強烈需求。這導致了對開發可以預防地中海貧血或減輕其嚴重程度的疫苗的大量投資。據估計，全球每年約有60,000 至100,000 名嬰兒出生時患有嚴重形式的BETA-地中海貧血，約佔全球人口的1.5%，約80-9000 萬是地中海貧血攜帶者，每年有60,000 人出生時患有地中海貧血。

地中海貧血治療市場包括輸血、鐵螯合療法和骨髓移植等多種療法。輸血是地中海貧血最常見的治療方法，因為它們有助於用健康的紅血球取代有缺陷的紅血球。然而，頻繁輸血會導致體內鐵過多，進而導致器官損傷和心臟衰竭等併發症。鐵螯合療法用於去除體內多餘的鐵，而骨髓移植被認為是地中海貧血的治療選擇。

地中海貧血治療市場的成長面臨多項挑戰，包括頻繁輸血、鐵螯合療法、有限競爭和獲得學名藥的機會有限導致的治療成本以及地中海貧血地區對疫苗猶豫不決和政治不穩定的趨勢。開發疫苗需要美國食品藥物管理局（FDA）和歐洲藥品管理局（EMA）等監管機構的批准。這個過程可能漫長且昂貴，而且批准要求可能很嚴格，使得小公司很難完成這個過程。

市場概況
預測期	2024-2028
2022 年市場規模	18.9億美元
2028 年市場規模	27.1億美元
2023-2028 年年複合成長率	6.14%
成長最快的細分市場	輸血
最大的市場	北美洲

地中海貧血盛行率增加

地中海貧血盛行率的增加是全球地中海貧血治療市場的主要驅動力之一。地中海貧血是一種遺傳性疾病，最常見於地中海、中東和亞洲血統的人。這些地區地中海貧血的高盛行率導致對有效治療方案的需求不斷成長，並預計全球地中海貧血治療市場的成長。

醫學科學的技術進步預示著市場的成長

醫學技術進步在推動全球地中海貧血治療市場方面發揮了重要作用。新技術和創新技術的發展促進了更有效的地中海貧血治療方法的開發，改善了患者的治療結果和生活品質，推動了全球地中海貧血治療市場的發展。

基因治療涉及將基因的功能性拷貝插入患者的細胞中以替換有缺陷或缺失的基因。 FDA 批准了地中海貧血基因治療，每位患者的費用為 280 萬美元。這種方法在地中海貧血的治療中顯示出有希望的結果，幾種正在開發的基因療法已顯示出顯著的療效，新的基因療法幫助超過90% 的輸血依賴性BETA地中海貧血成人和兒童患者實現了輸血獨立。

幹細胞移植涉及將健康幹細胞移植到地中海貧血患者體內。治療費用中位數為 12500 美元。這種方法可以為嚴重地中海貧血患者提供治療選擇，但需要相容的供體，並存在移植相關併發症的風險。從相匹配的非親緣供體處接受移植的患者的兩年無地中海貧血生存率為 71%，而從相匹配的相關供體處接受移植的患者的兩年無地中海貧血生存率為 82%。

Cas9是一項革命性的基因編輯技術，能夠精確地修飾DNA。該技術有潛力透過糾正潛在的遺傳缺陷為地中海貧血患者提供治療選擇，預計將推動全球地中海貧血治療市場的成長。

未滿足的醫療需求增加

未滿足的醫療需求的增加是全球地中海貧血治療市場成長的促進因素之一。地中海貧血是一種遺傳性疾病，會影響血紅素的產生，導致貧血和其他併發症。此疾病的嚴重程度差異很大，患有嚴重地中海貧血的患者需要定期輸血和其他支持性護理來控制症狀。一些地中海貧血治療方法的可用性，例如 Luspatercept 是一種治療需要定期輸血的 B 地中海貧血成人貧血的藥物，但在該患者群體中仍然存在顯著的未滿足的醫療需求。許多患者仍需要頻繁輸血並遭受與疾病相關的併發症。此外，目前的治療可能很昂貴，並且需要持續的監測和管理，這可能會給患者及其家人帶來負擔。對地中海貧血新的、更有效的治療方法的需求不斷成長，特別是那些可以為患者提供治療選擇的方法。這種需求推動了新療法的開發，例如基因療法和基因編輯，有可能治癒地中海貧血。新療法的開發，未滿足的醫療需求的增加為現有療法創造了不斷成長的市場，例如輸血和螯合療法。隨著地中海貧血的盛行率持續增加，特別是在發展中國家，對這些治療的需求預計將成長，從而推動全球地中海貧血治療市場的成長。

市場區隔

全球地中海貧血治療市場可以按類型和地區細分。根據類型，全球地中海貧血治療市場可分為輸血、鐵螯合療法、血液和骨髓移植等。從地區來看，地中海貧血治療市場可分為北美、歐洲、亞太地區、南美洲以及中東和非洲。

市場參與者

Bluebird Bio, Inc.、Acceleron Pharma, Inc.、Celgene Corporation、GlaxoSmithKline plc、Incyte Corporation、La Jolla Pharmaceutical Company、Ionis Pharmaceuticals, Inc.、Sanofi SA、Lonza Group Ltd. 和 ApoPharma Inc 是營運中的一些領先參與者在全球地中海貧血治療市場。

報告範圍：

在本報告中，除了以下詳細介紹的產業趨勢外，全球地中海貧血治療市場也分為以下幾類。

全球地中海貧血治療市場，按類型：

輸血
鐵螯合療法
血液和骨髓移植
其他

全球地中海貧血治療市場（按地區）：

北美洲
美國
加拿大
墨西哥
歐洲
德國
英國
法國
義大利
西班牙
亞太地區
中國
印度
馬來西亞
泰國
越南
南美洲
巴西
阿根廷
中東和非洲
南非
沙烏地阿拉伯
阿拉伯聯合大公國
埃及
巴林
卡達
科威特
土耳其

競爭格局

公司概況：全球地中海貧血治療市場主要公司的詳細分析。

可用的客製化：

根據給定的市場資料，TechSci Research 可根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

其他市場參與者（最多五個）的詳細分析和概況分析。

市場規模及預測
- 按價值
市佔率及預測
- 按類型（輸血、鐵螯合療法、血液和骨髓移植、其他）
- 按國家/地區
MEA：國家分析
- 埃及地中海貧血治療
- 南非地中海貧血治療
- 沙烏地阿拉伯地中海貧血治療
- 阿拉伯聯合大公國地中海貧血治療
- 巴林地中海貧血治療
- 卡達地中海貧血治療
- 科威特地中海型貧血治療
- 土耳其地中海貧血治療

第 13 章：市場動態

促進要素
挑戰

第 14 章：市場趨勢與發展

產品發布
併購
最近的發展

第 15 章：全球地中海貧血治療市場：SWOT 分析

第16章：波特的五力分析

產業競爭
新進入者的潛力
供應商的力量
客戶的力量
替代產品的威脅

第17章：競爭格局

商業概覽
公司概況
產品與服務
財務（上市公司）
最近的發展
SWOT分析
- Bluebird bio, Inc.
- Acceleron Pharma, Inc.
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- La Jolla Pharmaceutical Company
- Ionis Pharmaceuticals, Inc.
- Sanofi SA
- Lonza Group Ltd.
- ApoPharma Inc

第 18 章：策略建議

關於我們及免責聲明

簡介目錄

Product Code: 15590

Global thalassemia treatment market will witness an impressive growth during the forecast period, 2024-2028. This can be ascribed to the increasing prevalence of thalassemia and its treatment options. Thalassemia is a major public health problem in many developing countries, particularly in Mediterranean region. The high burden of disease has created a strong demand for effective thalassemia vaccines. This has led to significant investment in the development of vaccines that can prevent thalassemia or reduce its severity. It is estimated that there are around 60,000 to 100,000 babies born with severe forms of Beta-thalassemia each year globally, which is around 1.5% of the global population, around 80-90 million are carriers of thalassemia and 60000 individuals are born annually with thalassemia.

The thalassemia treatment market includes various types of therapies such as blood transfusions, iron chelation therapy, and bone marrow transplantation. Blood transfusions are the most common treatment for thalassemia, as they help to replace the defective red blood cells with healthy ones. However, frequent blood transfusions can lead to an excess buildup of iron in the body, which can cause complications such as organ damage and heart failure. Iron chelation therapy is used to remove excess iron from the body, while bone marrow transplantation is considered a curative option for thalassemia.

The growth of the Thalassemia treatment market faces several challenges, including treatment cost due to the frequent blood transfusions, Iron chelation therapy, limited competition, and limited access to generic drugs and the growing trend of vaccine hesitancy and political instability in thalassemic areas. Developing a vaccine requires approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This process can be lengthy and expensive, and the requirements for approval can be stringent, making it difficult for smaller companies to navigate the process.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD1.89 Billion
Market Size 2028	USD2.71 Billion
CAGR 2023-2028	6.14%
Fastest Growing Segment	Blood Transfusion
Largest Market	North America

Increasing Prevalence of Thalassemia

The increasing prevalence of thalassemia is one of the key drivers of the global thalassemia treatment market. Thalassemia is a genetic disorder that is most found in populations of Mediterranean, Middle East, and Asian descent. The high prevalence of thalassemia in these regions has resulted in growing demand for effective treatment options may be anticipated in the growth of Global thalassemia treatment market.

As the global population continues to grow, the number of people with thalassemia is expected to increase. According to the World Health Organization, thalassemia is one of the most common genetic disorders worldwide, with approximately 300,000 to 500,000 children born with the disease each year. Such increasing prevalence of thalassemia is expected to drive demand for thalassemia treatment market.

Pharmaceutical companies are investing heavily in research and development for new treatments for thalassemia, including gene therapy and fetal hemoglobin induction. These treatments have the potential to provide a curative option for patients with thalassemia, which could significantly improve patient outcomes and quality of life.

Bluebird Bio is developing a gene therapy called Zynteglo (autologous CD34+ cells encoding BA-T87Q-globin gene) for the treatment of transfusion-dependent B-thalassemia. Sangamo Therapeutics is developing a gene therapy called ST-400 for the treatment of B-thalassemia. Hence, it is expected to drive global thalassemia treatment market.

Technological Advancements In Medical Science Promises The Growth Of Market

Technological advancements in medical science have played a significant role in driving the global thalassemia treatment market. The development of new and innovative technologies has enabled the development of more effective treatments for thalassemia, improving patient outcomes and quality of life drives the market of global thalassemia treatment market.

Gene therapy involves the insertion of a functional copy of a gene into a patient's cells to replace a defective or missing gene. FDA approved thalassemia gene therapy treatment costing USD 2.8M per patient. This approach has shown promising results in the treatment of thalassemia, with several gene therapies in development that have shown significant efficacy new gene treatment helped more than 90% of adult and pediatric patients with transfusion-dependent beta-thalassemia achieve transfusion independence.

Stem cell transplantation involves the transplantation of healthy stem cells into a patient with thalassemia. The median cost for treatment is USD 12500. This approach can provide a curative option for patients with severe thalassemia, but it requires a compatible donor and carries the risk of transplant-related complications. Patients who got transplants from matched unrelated donors had a 71% 2-year thalassemia-free survival rate, compared to 82% for patients who received transplants from matched related donors.

Cas9 is a revolutionary gene editing technology that enables precise modification of DNA. This technology has the potential to provide a curative option for patients with thalassemia by correcting the underlying genetic defect is expected to drive the growth of Global Thalassemia Treatment Market.

Increase in Unmet Medical Needs

The increase in unmet medical need has been one of the driving factors behind the growth of the global thalassemia treatment market. Thalassemia is a genetic disorder that affects the production of hemoglobin, leading to anemia and other complications. The severity of the disease can vary widely, and patients with severe forms of thalassemia require regular blood transfusions and other supportive care to manage their symptoms. The availability of some treatments for thalassemia, such as Luspatercept is a treatment for anemia in adults with B-thalassemia who require regular blood transfusions, there remains a significant unmet medical need in this patient population. Many patients still require frequent transfusions and suffer from the complications associated with the disease. In addition, current treatments can be expensive and require ongoing monitoring and management, which can be burdensome for patients and their families. there is a growing demand for new and more effective treatments for thalassemia, particularly those that can provide a curative option for patients. This demand has driven the development of new treatments, such as gene therapy and gene editing, which has the potential to provide a cure for thalassemia the development of new treatments, the increase in unmet medical need has created a growing market for existing treatments, such as blood transfusions and chelation therapy. As the prevalence of thalassemia continues to increase, particularly in developing countries, the demand for these treatments is expected to grow, driving the growth of the global thalassemia treatment market.

Market Segmentation

Global thalassemia treatment market can be segmented by type and region. Based on type, the global thalassemia treatment market can be divided into blood transfusions, iron chelation therapy, blood & bone marrow transplant, and others. Regionally, the thalassemia treatment market can be categorized into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

Bluebird bio, Inc., Acceleron Pharma, Inc., Celgene Corporation, GlaxoSmithKline plc, Incyte Corporation, La Jolla Pharmaceutical Company, Ionis Pharmaceuticals, Inc., Sanofi S.A., Lonza Group Ltd., and ApoPharma Inc are some of the leading players operating in the global thalassemia treatment market.

Report Scope:

In this report, Global Thalassemia Treatment Market has been segmented into following categories, in addition to the industry trends which have also been detailed below.

Global Thalassemia Treatment Market, By Type:

Blood Transfusions
Iron Chelation Therapy
Blood & Bone Marrow Transplant
Others

Global Thalassemia Treatment Market, By Region:

North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Asia Pacific
China
India
Malaysia
Thailand
Vietnam
South America
Brazil
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Egypt
Bahrain
Qatar
Kuwait
Turkey

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Thalassemia Treatment Market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Impact of COVID-19 on Global Thalassemia Treatment Market

6. Clinical Trial Analysis

6.1. Ongoing Clinical Trials
6.2. Completed Clinical Trials
6.3. Terminated Clinical Trials
6.4. Breakdown of Pipeline, By Development Phase
6.5. Breakdown of Pipeline, By Status
6.6. Breakdown of Pipeline, By Study Type
6.7. Breakdown of Pipeline, By Region
6.8. Clinical Trials Heat Map

7. Global Thalassemia Treatment Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 7.2.2. By Region
- 7.2.3. By Company (2022)
7.3. Market Map
- 7.3.1. By Type
- 7.3.2. By Region

8. North America Thalassemia Treatment Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 8.2.2. By Country
8.3. North America: Country Analysis
- 8.3.1. United States Thalassemia Treatment Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 8.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 8.3.2. Canada Thalassemia Treatment Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 8.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 8.3.3. Mexico Thalassemia Treatment Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 8.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

9. Europe Thalassemia Treatment Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 9.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 9.2.2. By Country
9.3. Europe: Country Analysis
- 9.3.1. Germany Thalassemia Treatment Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 9.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 9.3.2. France Thalassemia Treatment Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 9.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 9.3.3. United Kingdom Thalassemia Treatment Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 9.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 9.3.4. Spain Thalassemia Treatment Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 9.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 9.3.5. Italy Thalassemia Treatment Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 9.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

10. Asia-Pacific Thalassemia Treatment Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 10.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 10.2.2. By Country
10.3. Asia-Pacific: Country Analysis
- 10.3.1. China Thalassemia Treatment Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 10.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 10.3.2. Malaysia Thalassemia Treatment Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 10.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 10.3.3. Thailand Thalassemia Treatment Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 10.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 10.3.4. Vietnam Thalassemia Treatment Market Outlook
  - 10.3.4.1. Market Size & Forecast
    - 10.3.4.1.1. By Value
  - 10.3.4.2. Market Share & Forecast
    - 10.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 10.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 10.3.5. India Thalassemia Treatment Market Outlook
  - 10.3.5.1. Market Size & Forecast
    - 10.3.5.1.1. By Value
  - 10.3.5.2. Market Share & Forecast
    - 10.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 10.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

11. South America Thalassemia Treatment Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 11.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 11.2.2. By Country
11.3. South America: Country Analysis
- 11.3.1. Brazil Thalassemia Treatment Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 11.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 11.3.2. Argentina Thalassemia Treatment Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 11.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

12. Middle East and Africa Thalassemia Treatment Market Outlook

12.1. Market Size & Forecast
- 12.1.1. By Value
12.2. Market Share & Forecast
- 12.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
  - 12.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.2.2. By Country
12.3. MEA: Country Analysis
- 12.3.1. Egypt Thalassemia Treatment Market Outlook
  - 12.3.1.1. Market Size & Forecast
    - 12.3.1.1.1. By Value
  - 12.3.1.2. Market Share & Forecast
    - 12.3.1.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.1.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.2. South Africa Thalassemia Treatment Market Outlook
  - 12.3.2.1. Market Size & Forecast
    - 12.3.2.1.1. By Value
  - 12.3.2.2. Market Share & Forecast
    - 12.3.2.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.2.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.3. Saudi Arabia Thalassemia Treatment Market Outlook
  - 12.3.3.1. Market Size & Forecast
    - 12.3.3.1.1. By Value
  - 12.3.3.2. Market Share & Forecast
    - 12.3.3.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.3.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.4. UAE Thalassemia Treatment Market Outlook
  - 12.3.4.1. Market Size & Forecast
    - 12.3.4.1.1. By Value
  - 12.3.4.2. Market Share & Forecast
    - 12.3.4.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.4.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.5. Bahrain Thalassemia Treatment Market Outlook
  - 12.3.5.1. Market Size & Forecast
    - 12.3.5.1.1. By Value
  - 12.3.5.2. Market Share & Forecast
    - 12.3.5.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.5.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.6. Qatar Thalassemia Treatment Market Outlook
  - 12.3.6.1. Market Size & Forecast
    - 12.3.6.1.1. By Value
  - 12.3.6.2. Market Share & Forecast
    - 12.3.6.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.6.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.7. Kuwait Thalassemia Treatment Market Outlook
  - 12.3.7.1. Market Size & Forecast
    - 12.3.7.1.1. By Value
  - 12.3.7.2. Market Share & Forecast
    - 12.3.7.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.7.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))
- 12.3.8. Turkey Thalassemia Treatment Market Outlook
  - 12.3.8.1. Market Size & Forecast
    - 12.3.8.1.1. By Value
  - 12.3.8.2. Market Share & Forecast
    - 12.3.8.2.1. By Type (Blood Transfusions, Iron Chelation Therapy, Blood & Bone Marrow Transplant, Others)
    - 12.3.8.2.1.1. By Iron Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), Desferal (deferoxamine))

13. Market Dynamics

13.1. Drivers
13.2. Challenges

14. Market Trends & Developments

14.1. Product Launches
14.2. Mergers & Acquisitions
14.3. Recent Developments

15. Global Thalassemia Treatment Market: SWOT Analysis

16. Porter's Five Forces Analysis

16.1. Competition in the Industry
16.2. Potential of New Entrants
16.3. Power of Suppliers
16.4. Power of Customers
16.5. Threat of Substitute Products

17. Competitive Landscape

17.1. Business Overview
17.2. Company Snapshot
17.3. Products & Services
17.4. Financials (In case of listed companies)
17.5. Recent Developments
17.6. SWOT Analysis
- 17.6.1. Bluebird bio, Inc.
- 17.6.2. Acceleron Pharma, Inc.
- 17.6.3. Celgene Corporation
- 17.6.4. GlaxoSmithKline plc
- 17.6.5. Incyte Corporation
- 17.6.6. La Jolla Pharmaceutical Company
- 17.6.7. Ionis Pharmaceuticals, Inc.
- 17.6.8. Sanofi S.A.
- 17.6.9. Lonza Group Ltd.
- 17.6.10. ApoPharma Inc